Athenex Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Athenex han disminuido a una tasa media anual de -7.6%, mientras que en la industria Biotechs los beneficios crecieron en un 17.7% anualmente. Los ingresos han ido creciendo a una tasa media de 11.2% al año.

Información clave

-7.6%

Tasa de crecimiento de los beneficios

9.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	-14.6%
Tasa de crecimiento de los ingresos	11.2%
Rentabilidad financiera	n/a
Margen neto	-95.3%
Última actualización de beneficios	31 Dec 2022

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Athenex. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:2MT0 Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 22	103	-98	49	52
30 Sep 22	123	-178	70	56
30 Jun 22	121	-192	71	65
31 Mar 22	109	-198	67	71
31 Dec 21	95	-158	57	78
30 Sep 21	113	-132	75	78
30 Jun 21	117	-135	83	79
31 Mar 21	137	-144	86	80
31 Dec 20	144	-142	93	76
30 Sep 20	157	-118	84	79
30 Jun 20	141	-116	78	80
31 Mar 20	123	-108	77	101
31 Dec 19	101	-123	66	84
30 Sep 19	88	-129	60	65
30 Jun 19	87	-141	55	46
31 Mar 19	77	-145	51	3
31 Dec 18	89	-117	49	120
30 Sep 18	83	-119	50	0
30 Jun 18	78	-96	49	0
31 Mar 18	71	-97	49	0
31 Dec 17	38	-131	46	2
30 Sep 17	28	-143	44	0
30 Jun 17	20	-144	40	0
31 Mar 17	21	-118	31	0
31 Dec 16	21	-88	26	0
30 Sep 16	21	-61	21	0

Ingresos de calidad: 2MT0 actualmente no es rentable.

Margen de beneficios creciente: 2MT0 actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 2MT0 no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 7.6% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 2MT0 en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 2MT0 no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).

Rentabilidad financiera

Alta ROE: El pasivo de 2MT0 supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Athenex Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.33 loss in 3Q 2021)

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.27 loss in 1Q 2021)

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Insufficient new directors

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.33 loss in 3Q 2021)

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.27 loss in 1Q 2021)

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought €54k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought €136k worth of stock

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc

Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders

Insider recently sold €1.6m worth of stock

Independent Director recently sold €385k worth of stock

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Full year 2020 earnings released: US$1.72 loss per share (vs US$1.67 loss in FY 2019)

New 90-day low: €4.52

Revenue beats expectations

Athenex, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Athenex, Inc. Enters into Second Amendment to the License Agreement

Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)

New 90-day high: €11.80

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

New 90-day low: €9.45

Athenex, Inc. Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer

Revenue beats expectations

Third quarter 2020 earnings released: US$0.44 loss per share

Athenex, Inc. Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy

Independent Director recently bought €188k worth of stock

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

New 90-day high - €12.20

New 90-day low - €8.85

Athenex, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Desglose de ingresos y gastos
Beta